It is noteworthy that activating point mutations across any of the components of the pathway have been known as either trigger of cancer (mutations of RAF and RAS family genes) or as poor prognosis indicator (mutations of ERK and MEK) [114, 116]. This evidence concerns the gene MAPK1 and cancer.